Our Review Summary
In contrast to the TIME article on this study (which we reviewed), and some others, the Reuters piece is appropriately skeptical and far more business-oriented, paying substantial detail to costs, harms, and regulatory challenges and cautions. It is skimpier than than the TIME article on some of the biological novelty of the new drug, but overall does a better job of informing readers and professionals of the slow slog many novel drugs must take before they are demonstrated safe, effective and affordable for those who may benefit.
Why This Matters
The anti-inflammatory scientific arc is littered with the consequences of less-than-stellar clinical results, overblown expectations and pharmaceutical industry high-stakes business gambles. That makes it especially important for news organizations to cover the subject area with the utmost care and context–this story took pains to do so.
Criteria
Satisfactory
This article does a great job of noting the cost and pricing issues inherent in the drug company’s efforts to develop, test and market novel biologicals. The headlong rush to “personalized” medicine, pharmacogenetic approaches to treatment, limited resources even in wealthy nations with gold-plated insurance policies, and the opacity of drug industry research costs make it imperative to explain to the public the realities of medicine’s pricing system.
Not Satisfactory
The thoughtful reader will understand that the benefits are modest, as indicated by the well-written headline and carefully worded opening sentence. However, missing from the story was a discussion of the study findings in absolute terms.
The story says the study that “heart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo.”
What does this mean in absolute numbers? The way researchers measured it was in events per 100 person-years, and the “events” were non-fatal heart attack, non-fatal stroke, or death from a cardiovascular reason. In the placebo group, there were 4.50 cardiac events per 100 person-years. In the group receiving 150 mg doses of canakinumab, there were 3.86 events per 100 person years. Of the various doses given (50, 150 and 300 milligrams), the 150 mg dose was the only statistically significant result, and it was only because of non-fatal heart attacks.
Satisfactory
From the get-go, readers are told there are risks to keep in mind. This was entirely absent from the TIME story we reviewed.
That said, we wish this Reuters story had discussed the harms more in-depth–how frequent were they? How severe?
Not Satisfactory
This was a randomized, placebo controlled clinical trial with a large number of patients. The story doesn’t explain this, nor any of the study’s limitations.
Satisfactory
No mongering here.
Satisfactory
This story, which is more of a “business of medicine” story, uses a drug industry analyst source to good effect, and included commentary from the study’s accompanying editorial.
Not Satisfactory
Both this story and the TIME story don’t mention that there are many effective and less expensive alternatives to secondary cardiac disease prevention, such as smoking cessation, aspirin, statins, blood pressure control, etc.
Satisfactory
The lede graph says “Novartis will seek regulatory approval” for the drug’s use against heart disease, “though some experts fear fatal infection risks and a high price may overshadow the medicine’s limited scientific benefits.” At least for now.
Satisfactory
The story does a pretty good job of explaining what is novel about the the drug’s effects and targeting.
Satisfactory
The story does not appear to rely on the news release.
Total Score: 7 of 10 Satisfactory
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like